Paragraph IV Challenges

✉ Email this page to a colleague

+ Get email alerts for changes to this table

Subscribe to access the full database, or Get Started Free
Tradename	Dosage	Generic Name	NDA	ANDAs Submitted	180 Day Exclusivity Status	Submissiondate
TAFINLAR	Capsules	dabrafenib mesylate	202806	1		2025-11-13
TAVNEOS	Capsules	avacopan	214487	3		2025-11-13
LIVMARLI	Oral Solution	maralixibat chloride	214662	3		2025-09-29
QULIPTA	Tablets	atogepant	215206	6		2025-09-29
KORSUVA	Intravenous Solution	difelikefalin acetate	214916	5		2025-08-25
NOURIANZ	Tablets	istradefylline	022075	1		2025-08-13
>Tradename	>Dosage	>Generic Name	>NDA	>ANDAs Submitted	>180 Day Exclusivity Status	>Submissiondate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.